Tingbo Liang

机构：Verizon (United States), RTI International, Anhui Medical University, Zhejiang Cancer Hospital, Zhejiang Technical Institute of Economics, National Center for Chronic and Noncommunicable Disease Control and Prevention, Zhejiang Lab, First Affiliated Hospital of Anhui Medical University, Shanghai Clinical Research Center, Pancreas Centre (Canada), Zhejiang Medicine (China), First Affiliated Hospital Zhejiang University, Zhejiang University · ORCID：0000-0003-0143-3353

发表论文 498 篇 · 总被引 18203 次 · h-index 67

代表论文

• Oncolytic virus VG161 in refractory hepatocellular carcinoma (2025 · Nature · 被引 82)
• Clinical development of immuno-oncology therapeutics (2025 · Cancer Letters · 被引 50)
• Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial (2025 · Hepatology · 被引 28)
• First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 14)
• Harnessing amino acid pathways to influence myeloid cell function in tumor immunity (2025 · Molecular Medicine · 被引 13)
• Cancer dormancy and metabolism: From molecular insights to translational opportunities (2025 · Cancer Letters · 被引 12)